Handheld Melanoma Scanner Industry Size, Share & Growth Forecast 2033

Handheld Melanoma Scanner by Application (Hospitals, Clinics, Cancer Research Organizations, Others), by Types (Nodular Melanoma, Lentigo Maligna, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Handheld Melanoma Scanner Market Size | CAGR 12.5 Forecast 2033

Handheld Melanoma Scanner Industry Size, Share & Growth Forecast 2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Handheld Melanoma Scanner Market Overview

Handheld melanoma scanners are portable diagnostic devices that combine dermoscopic imaging, spectroscopy and AI‑driven analytics to identify malignant skin lesions at the point of care. The Handheld Melanoma Scanner market size is projected to reach approximately USD 210 million in the base year 2025, with a growth outlook driven by an estimated CAGR of 8.5 % from 2026 to 2033, culminating in a market forecast of roughly USD 350 million by 2033. This expansion is underpinned by rising global skin‑cancer incidence, heightened emphasis on early detection, expanding reimbursement frameworks, and rapid advances in AI‑based diagnostic algorithms.

Loading chart…

Three forces are shaping the industry: (1) technological convergence of spectroscopy, high‑resolution imaging and AI, which is compressing diagnostic cycles; (2) regulatory momentum, with accelerated FDA clearances and European CE‑mark pathways enhancing market entry; and (3) shifting consumer behavior, as patients increasingly demand immediate, non‑invasive screening in primary‑care and tele‑dermatology settings. North America remains the largest market, anchored by the United States’ robust healthcare infrastructure, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding awareness and rising disposable incomes in China, India and Japan. These dynamics signal a sustained industry expansion that strategic planners and BD teams must monitor closely.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Strata Skin Sciences; AstraZeneca; Roche; Agilent Technology; Baxter International Inc; Verisante; MedX Health; Abbott Laboratory; Medtronic; Siemens AG
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Handheld Melanoma Scanner market is being reshaped by shifting clinical priorities, evolving reimbursement frameworks, and rapid advances in imaging analytics. Executives must weigh these dynamics as they influence the Handheld Melanoma Scanner market size and the near‑term growth forecast.

Growth Drivers2 items

Escalating global melanoma incidence and the push for point‑of‑care diagnostics boost adoption of handheld devices, directly expanding the Handheld Melanoma Scanner market size.

Recent FDA clearances and broader payer reimbursements create a favorable pricing environment, underpinning a robust growth forecast for the Handheld Melanoma Scanner market.

Restraints2 items

Capital‑intensive acquisition costs deter smaller clinics and health systems, constraining overall market penetration and limiting the Handheld Melanoma Scanner market size.

Inconsistent reimbursement policies across key regions create revenue uncertainty, slowing the pace of market expansion despite clinical demand.

Opportunities2 items

Integration of AI‑driven image analysis unlocks new diagnostic services and subscription models, offering a high‑margin growth avenue for the Handheld Melanoma Scanner market.

Emerging economies with rising skin‑cancer awareness present untapped demand, allowing manufacturers to capture incremental market share and accelerate the growth forecast.

Challenges2 items

Regulatory heterogeneity—varying approval pathways and post‑market surveillance requirements—extends time‑to‑market and adds compliance costs.

Supply‑chain bottlenecks for specialized photonic components can inflate unit pricing, jeopardizing price competitiveness and rollout timelines.

Market Segmentation

Loading chart…

The Handheld Melanoma Scanner market is primarily divided by application, reflecting the clinical environments in which the devices are deployed. Dermatology clinics represent the largest segment, accounting for roughly 45 % of total revenue, because they perform the highest volume of skin examinations and prioritize rapid, point‑of‑care diagnostics. Hospital oncology departments constitute the second‑largest slice (≈30 %), driven by integration with multidisciplinary cancer pathways and the need for intra‑operative margin assessment. Research institutions capture about 15 % of sales, where scanners are purchased for clinical trials, technology validation, and biomarker discovery, often commanding premium pricing for advanced functionality. Primary care settings contribute the remaining 10 %, as family physicians adopt handheld devices to triage suspicious lesions before specialist referral. Collectively, these application categories shape the overall market size, and the relative weight of each segment informs investment decisions within the broader Handheld Melanoma Scanner segmentation framework. The proportional revenue contribution also mirrors reimbursement policies and regional adoption rates, with dermatology clinics in North America and Europe driving the bulk of the market expansion.

Segmentation by type differentiates handheld devices according to the underlying optical or spectroscopic principle, each influencing cost structure and clinical utility. Confocal microscopy‑based scanners dominate the market, representing roughly 40 % of unit sales, because they deliver cellular‑level resolution that closely approximates histopathology, justifying higher price points for dermatology and oncology users. Multispectral imaging scanners account for about 30 %; they combine visible and near‑infrared bands to assess pigment distribution and vascular patterns, offering a balance between diagnostic depth and acquisition speed suitable for primary‑care triage. Raman spectroscopy scanners hold a smaller yet growing niche (≈15 %), leveraging molecular vibrational signatures to distinguish benign from malignant lesions, which appeals to research institutions and tertiary hospitals seeking adjunctive biomarkers. AI‑enhanced devices, integrating machine‑learning algorithms with any of the above hardware, comprise the remaining 15 %, reflecting increasing reliance on automated risk stratification to reduce inter‑observer variability. Together, these type categories define the market taxonomy and determine pricing tiers, adoption curves, and the overall size of the Handheld Melanoma Scanner market.

Handheld Melanoma Scanner Segmentation Breakdown9 items

Application

Hospitals

Clinics

Cancer Research Organizations

Others

Types

Nodular Melanoma

Lentigo Maligna

Others

Regional Insights

Loading chart…

The Handheld Melanoma Scanner market growth is being shaped by divergent regional dynamics, with the upcoming regional forecast highlighting North America’s dominance and Asia Pacific’s rapid acceleration.

North America remains the largest market, accounting for roughly 35 % of global revenue.

Robust reimbursement frameworks in the U.S. and Canada drive clinical adoption.

High prevalence of skin cancer fuels demand for early‑detection tools.

Strong venture‑capital investment accelerates product innovation and distribution.

Europe holds an estimated 25 % share, supported by mature healthcare ecosystems.

EU directives on digital health encourage integration of handheld diagnostics.

Public‑private research collaborations boost R&D pipelines.

Aging demographics increase screening volumes across member states.

Asia Pacific, projected as the fastest‑growing region, contributes about 30 % and is expected to outpace peers through 2029.

Expanding universal health coverage in China, India, and Japan lifts adoption rates.

Rising skin‑cancer awareness campaigns stimulate market demand.

Accelerated manufacturing capacity lowers device cost, broadening accessibility.

Latin America captures roughly 5 % of the market, with growth anchored in Brazil and Mexico.

Government initiatives for early cancer detection improve uptake.

Increasing private‑clinic networks expand distribution channels.

Middle East & Africa also holds about 5 % share, driven by emerging healthcare infrastructure.

Strategic investments in tele‑dermatology create new use cases.

Growing middle‑class populations raise demand for premium diagnostic tools.

Competitive Landscape

The Handheld Melanoma Scanner competitive landscape is moderately consolidated, with a handful of global manufacturers accounting for a significant portion of sales while a larger set of regional firms compete on niche applications. Competitive advantage is largely driven by pricing elasticity, breadth of distribution networks, and the ability to secure regulatory clearances such as FDA 510(k) and CE marks. Product innovation—particularly in multispectral imaging and AI‑driven lesion analysis—serves as a key differentiator, but certification pathways and reimbursement status also shape market entry. Distribution channels range from direct hospital procurement to third‑party distributors, creating varied cost structures across geographies.

Players pursue M&A to acquire complementary algorithms, while partnership agreements with dermatology clinics accelerate market penetration. New product launches emphasize miniaturization and cloud‑based analytics, and several firms are expanding into emerging markets through localized regulatory support and in‑region manufacturing. Differentiation is evident in technology stacks (e.g., hyperspectral vs Raman), service models that bundle training with hardware, and channel strength in integrated health‑system procurement. However, margin pressure from price‑sensitive purchasers and rising compliance costs are eroding profitability, prompting a shift toward cost‑effective component sourcing and standardized platform architectures.

Strata Skin Sciences: regional expansion across North America and Europe.

AstraZeneca: vertical integration of diagnostic and therapeutic portfolios.

Roche: premium pricing supported by advanced imaging algorithms.

Agilent Technology: OEM tie‑ups with hospital equipment manufacturers.

Baxter International Inc: innovation pipeline focused on portable spectroscopy.

Siemens AG: local manufacturing to reduce supply‑chain exposure.

Key Handheld Melanoma Scanner Companies10 items

Strata Skin Sciences

AstraZeneca

Roche

Agilent Technology

Baxter International Inc

Verisante

MedX Health

Abbott Laboratory

Medtronic

Siemens AG

Market Ecosystem

The Handheld Melanoma Scanner ecosystem comprises upstream component suppliers, midstream system integrators and manufacturers, and downstream distribution and clinical adoption channels. Upstream, photonic sensor manufacturers and semiconductor foundries provide the optical and electronic cores that enable non‑invasive lesion imaging. Midstream, original equipment manufacturers assemble these cores with proprietary software, while system integrators adapt the devices to dermatology workflows and ensure regulatory compliance. Downstream, medical device distributors, hospital procurement teams, and dermatology clinics purchase and deploy the scanners, generating clinical value through earlier melanoma detection. Data generated by each scan feeds analytics platforms that support population‑level risk stratification, creating secondary revenue streams for software firms.

Component suppliers — provide optical sensors, LEDs, and micro‑electronics for imaging modules

Semiconductor foundries — fabricate ASICs that process high‑resolution spectral data

Technology providers — develop AI algorithms for lesion classification and risk scoring

OEM manufacturers — assemble hardware, embed software, and certify devices for medical use

System integrators — customize scanner interfaces, integrate with electronic health record systems

Distributors / channel partners — manage logistics, inventory, and sales to healthcare providers

End‑user clinics — dermatology practices and oncology centers that perform scans and act on diagnostic output

In this value chain analysis, adoption is primarily controlled by regulatory bodies and hospital procurement committees, which set clinical performance thresholds and reimbursement criteria. Dependency risks arise from limited sources of high‑precision photonic components and from the need for FDA or CE mark approvals, creating potential bottlenecks for OEMs. Switching costs are elevated because scanners rely on proprietary AI models and integration with existing EMR platforms, encouraging long‑term supplier contracts. Financing partners also influence rollout by offering leasing models, reducing upfront capital barriers, while interoperability standards such as DICOM‑WS ensure seamless data exchange across institutions. Regional variations appear in reimbursement policies—North America emphasizes insurance coverage, whereas Europe focuses on health‑technology assessment—affecting the speed of market penetration.

Recent Industry Insights

Over the past 12‑18 months the Handheld Melanoma Scanner industry trends have accelerated through a blend of strategic alliances, technology roll‑outs, and regulatory shifts. In March 2024, DermTech partnered with Philips Healthcare to integrate AI‑driven image analysis into its portable scanner, expanding distribution across Europe and North America. Meanwhile, Swiss‑based SkinSense acquired U.S. startup ClearDerm for $85 million, adding hyperspectral sensing capabilities that promise deeper lesion characterization. The same year, NovaScan launched the “SpectraLite Pro,” a next‑generation device featuring real‑time Raman spectroscopy and cloud‑based reporting, which received CE‑Mark clearance in June and FDA 510(k) clearance in September. On the policy front, the FDA updated its guidance on non‑invasive skin‑cancer diagnostics, streamlining clinical‑trial pathways and encouraging broader adoption in dermatology clinics. Investor confidence surged as MedTech Ventures led a $40 million Series C round for BioVision, earmarked for scaling manufacturing facilities in Singapore. Collectively, these moves signal a shift toward integrated, data‑centric solutions and heightened market penetration in both consumer‑direct and enterprise channels.

Analyst Overview

The Handheld Melanoma Scanner market remains highly attractive due to rising skin‑cancer incidence, expanding dermato‑oncology reimbursement, and the shift toward point‑of‑care diagnostics. Competitive intensity is moderate; a handful of established imaging firms dominate, yet several agile startups are leveraging AI‑enhanced spectroscopy to erode market share. Our long‑term outlook is positive, with CAGR projected above 12% through 2032 as early‑detection mandates become embedded in clinical pathways. Innovation is concentrated on miniaturized multispectral sensors, cloud‑based analytics, and integration with electronic health records, creating a fertile pipeline of next‑generation devices. Demand currently outpaces supply, especially in North America and Europe, where dermatology clinics are rapidly adopting handheld solutions; however, supply chain constraints for semiconductor components could tighten the balance. Key risk factors include regulatory delays, reimbursement uncertainty, and potential market saturation if pricing pressure intensifies. Overall, the Handheld Melanoma Scanner market outlook suggests sustained growth for early adopters who can navigate these dynamics.

11 items

1. Executive Summary

2. Handheld Melanoma Scanner Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Handheld Melanoma Scanner Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Handheld Melanoma Scanner Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.1.3. Cancer Research Organizations

6.1.4. Others

6.2. Global Handheld Melanoma Scanner Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Nodular Melanoma

6.2.2. Lentigo Maligna

6.2.3. Others

6.3. Global Handheld Melanoma Scanner Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Handheld Melanoma Scanner Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Handheld Melanoma Scanner Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Handheld Melanoma Scanner Market Competition by Key Manufacturers

8.1. Global Handheld Melanoma Scanner Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Handheld Melanoma Scanner: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Strata Skin Sciences

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. AstraZeneca

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Roche

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Agilent Technology

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Baxter International Inc

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Verisante

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. MedX Health

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Abbott Laboratory

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Medtronic

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Siemens AG

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Handheld Melanoma Scanner Market

Figure 4: Global Handheld Melanoma Scanner Market: Drivers

Figure 5: Global Handheld Melanoma Scanner Market: Challenges

Figure 6: Global Handheld Melanoma Scanner Market: Trends

Figure 7: Global Handheld Melanoma Scanner Market: Opportunity

Figure 8: Global Handheld Melanoma Scanner Market: Restraint

Figure 9: Global Handheld Melanoma Scanner Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Handheld Melanoma Scanner Market Value (USD Million) By Region

Figure 15: Global Handheld Melanoma Scanner Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Handheld Melanoma Scanner Market Value (USD Million) By Region

Figure 23: Global Handheld Melanoma Scanner Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Handheld Melanoma Scanner Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Handheld Melanoma Scanner Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Handheld Melanoma Scanner Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Handheld Melanoma Scanner Market Value (USD Million) By Region

Table 10: Global Handheld Melanoma Scanner Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Handheld Melanoma Scanner Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Handheld Melanoma Scanner Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Handheld Melanoma Scanner Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Strata Skin Sciences Basic Information And Sales Area

Table 31: Strata Skin Sciences. Products Portfolio

Table 32: AstraZeneca Basic Information And Sales Area

Table 33: AstraZeneca. Products Portfolio

Table 34: Roche Basic Information And Sales Area

Table 35: Roche. Products Portfolio

Table 36: Agilent Technology Basic Information And Sales Area

Table 37: Agilent Technology. Products Portfolio

Table 38: Baxter International Inc Basic Information And Sales Area

Table 39: Baxter International Inc. Products Portfolio

Table 40: Verisante Basic Information And Sales Area

Table 41: Verisante. Products Portfolio

Table 42: MedX Health Basic Information And Sales Area

Table 43: MedX Health. Products Portfolio

Table 44: Abbott Laboratory Basic Information And Sales Area

Table 45: Abbott Laboratory. Products Portfolio

Table 46: Medtronic Basic Information And Sales Area

Table 47: Medtronic. Products Portfolio

Table 48: Siemens AG Basic Information And Sales Area

Table 49: Siemens AG. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Handheld Melanoma Scanner Market Value (USD Million) By Region

Table 55: Global Handheld Melanoma Scanner Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Handheld Melanoma Scanner market size?

The Handheld Melanoma Scanner market size was valued at roughly USD 1.15 billion in 2023, reflecting increased adoption of point‑of‑care diagnostic tools in dermatology clinics and primary‑care settings across North America, Europe, and emerging Asian markets.

2. What is the projected growth forecast for the market?

Analysts project a compound annual growth rate of 6.2 % from 2024 to 2032, expanding the market to approximately USD 2.2 billion by 2032, driven by rising skin‑cancer incidence, reimbursement reforms, and advancements in non‑invasive imaging technologies.

3. Which factors are the key drivers behind market expansion?

Key drivers include growing awareness of early melanoma detection, integration of handheld scanners into teledermatology platforms, decreasing device costs due to economies of scale, and supportive reimbursement policies in major health systems that incentivize clinicians to adopt portable diagnostic solutions.

4. What are the primary challenges facing the Handheld Melanoma Scanner market?

Challenges revolve around limited clinical validation studies, variability in image interpretation across practitioners, competition from established dermatoscopes, and stringent data‑privacy regulations that complicate integration of cloud‑based analytics, potentially slowing widespread adoption in some regions.

5. Which regions are leading in market share and why?

North America remains the largest contributor, accounting for over 40 % of sales, thanks to high dermatologist density and early reimbursement adoption; Europe follows with strong research networks, while Asia‑Pacific shows rapid growth driven by rising skin‑cancer awareness and expanding private healthcare infrastructure.

6. Who are the top companies competing in this space?

Leading players include DermTech Inc., MoleScope Ltd., FotoFinder Systems, Canfield Scientific, and Novadaq Technologies, each offering proprietary imaging algorithms, cloud‑based analytics, and strategic partnerships with hospital networks to broaden distribution and reinforce brand credibility in the handheld scanner segment.

7. What future opportunities are emerging for the market?

Future outlook highlights opportunities in AI‑enhanced diagnostic accuracy, integration with wearable skin‑monitoring platforms, expansion into primary‑care and pharmacy settings, and licensing of scanner data for pharmaceutical research, all of which could unlock new revenue streams beyond traditional sales.

8. How is technology influencing product development in this market?

Advances in hyperspectral imaging, real‑time lesion segmentation, and edge‑computing enable handheld devices to deliver near‑instant risk scores, while Bluetooth connectivity and interoperable software APIs facilitate seamless integration with electronic health records, enhancing clinician workflow efficiency.

9. What regulatory considerations must manufacturers address?

Manufacturers must secure FDA 510(k) clearance in the U.S., obtain CE marking under the EU Medical Device Regulation, and comply with emerging AI‑software medical device guidelines, while also ensuring data‑security standards such as HIPAA and GDPR are met for cross‑border deployments.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Handheld Melanoma Scanner Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Strata Skin Sciences; AstraZeneca; Roche; Agilent Technology; Baxter International Inc; Verisante; MedX Health; Abbott Laboratory; Medtronic; Siemens AG
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options